0001593968-22-000613.txt : 20220303
0001593968-22-000613.hdr.sgml : 20220303
20220303160620
ACCESSION NUMBER: 0001593968-22-000613
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220301
FILED AS OF DATE: 20220303
DATE AS OF CHANGE: 20220303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hopper Jonathan Mark
CENTRAL INDEX KEY: 0001626325
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35280
FILM NUMBER: 22708668
MAIL ADDRESS:
STREET 1: 64 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vericel Corp
CENTRAL INDEX KEY: 0000887359
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943096597
STATE OF INCORPORATION: MI
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 7349305555
MAIL ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC
DATE OF NAME CHANGE: 19960428
4
1
primary_01.xml
PRIMARY DOCUMENT
X0306
4
2022-03-01
0000887359
Vericel Corp
VCEL
0001626325
Hopper Jonathan Mark
C/O VERICEL CORPORATION
64 SIDNEY STREET
CAMBRIDGE
MA
02139
false
true
false
false
Chief Medical Officer
Common Stock
2022-03-01
4
M
false
10000
10.95
A
55914
D
Common Stock
2022-03-01
4
S
false
10000
41.406
D
45914
D
Common Stock
2022-03-01
4
M
false
10000
18
A
55914
D
Common Stock
2022-03-01
4
S
false
6738
41.462
D
49176
D
Stock Option (right to buy)
10.95
2022-03-01
4
M
false
10000
0
D
2028-08-20
Common Stock
10000
37604
D
Stock Option (right to buy)
18
2022-03-01
4
M
false
10000
0
D
2030-02-11
Common Stock
10000
38750
D
These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021.
These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company.
These options, representing the right to purchase 48,750 shares, became exercisable in quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 11, 2020.
/s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
2022-03-03